1. Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer.
- Author
-
Rapoport BL, Theron AJ, Vorobiof DA, Langenhoven L, Hall JM, Van Eeden RI, Smit T, Chan SW, Botha MC, Raats JI, Necker M, and Anderson R
- Abstract
Aim: We investigated the prognostic potential of pretherapy measurement of the neutrophil/lymphocyte ratio (NLR) in patients (n = 56) with non-small-cell lung cancer deemed suitable for treatment with nivolumab., Materials & Methods: This was a multicenter, noninterventional, retrospective data analysis, involving five oncology centers., Results: Patients with prenivolumab NLR values of <5 and ≥5 had respective median overall survival (OS) values of 14.5 and 7.02 months (p = 0.0026). Patients with ≤2 and >2 metastatic sites had median OS values of 11.4 and 6.1 months, respectively (p = 0.0174). A Cox multiple regression model revealed baseline NLR ≥5 as the only variable significantly associated with decreased OS (p < 0.0447)., Conclusion: Pretreatment elevated NLR values are associated with poor outcomes in patients with recurrent metastatic non-small-cell lung cancer treated with nivolumab., Competing Interests: Financial & competing interests disclosure BL Rapoport reports personal fees from Merck and Co, grants and personal fees from BMS, grants and personal fees from Roche South Africa, personal fees from AstraZeneca, during the conduct of the study. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. The final manuscript was supported in its entirety by the investigators. No writing assistance was utilized in the production of this manuscript., (© 2020 Rapoport BL.)
- Published
- 2020
- Full Text
- View/download PDF